Abstract
The current R&D outsourcing market is growing annually at ∼15%, with a predicted market of US$36 billion by 2010. However, top tier contract research organizations (CROs) are attempting to transform their profitability by focusing on higher value-added services, such as preclinical and bioanalytical testing, leading to a shortage of high-quality formulation CROs
| Original language | English |
|---|---|
| Pages (from-to) | 1405-1407 |
| Number of pages | 3 |
| Journal | Drug Discovery Today |
| Volume | 10 |
| Issue number | 21 |
| DOIs | |
| Publication status | Published - 1 Nov 2005 |